Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic ...

The novel Cleavage High-throughput Assay (CHiTA) developed at Penn State provides a scarless method to characterize thousands of diverse small self-cleaving RNA enzymes, called twister ribozymes, in a ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

Researchers at The Institute of Cancer Research have found a dual genetic test is more accurate than the traditional approach in identifying multiple myeloma patients who may be at an elevated risk of ...

Dr. Kayvan Zainabadi (center) is working with colleagues in Pune, India, to test the RNA-based TB diagnostic he is developing. From left: Dr. Mandar Paradkar (co-PI, pediatrician), Vidyulata Kamble, ...

Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). This is ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor Plus as well as its Liquid Trace Hematology ...

Promega, a global manufacturer of reagents, assays and benchtop instruments essential for COVID-19 research, drug development and diagnostic testing, including RNA extraction, increased production ...

Company secures $5M in funding to accelerate its rapid testing platformUSP<1223> Validation achieved, reinforcing 20-hour testing ...